Stocks Health care CAPR
NASDAQ · Health careCapricor Therapeutics, Inc. (CAPR)
It posted a net loss of $129.4M. In fiscal 2025 capital spending exceeded operating cash flow by $72.7M. At June 30, 2026 it held $20.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Capricor Therapeutics, Inc.
- Net worth
- Capricor Therapeutics, Inc. has a market value (market cap) of $515.7M at the latest share price, and shareholders' equity of $246.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $105M.
- Cash flow
- In fiscal 2025 operations used $69.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Capricor Therapeutics, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Capricor Therapeutics, Inc. does
Capricor Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CAPR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$105M | -$2.26 | -$72.7M |
| 2024 | $22.3M | -$40.5M | -$1.15 | -$41.2M |
| 2023 | $25.2M | -$22.3M | -$0.83 | -$26.9M |
| 2022 | $2.6M | -$29M | -$1.18 | $2.9M |
| 2021 | $244.9K | -$20M | -$0.87 | -$18M |
| 2020 | $310.3K | -$13.7M | -$0.88 | -$10.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Capricor Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 14, 2026Passive stake changed SCHEDULE 13G/A
- September 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 24, 2026Other event 8-K
- August 19, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 3, 2026Passive stake (5% or more) SCHEDULE 13G
- July 30, 2026Other event 8-K
Insider trades
What the people running Capricor Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 25, 2026 | Krasney KarenEVP, GENERAL COUNSEL | Exercised options | 24,100 | $76.6K |
| June 25, 2026 | Krasney KarenEVP, GENERAL COUNSEL | Soldpre-planned (10b5-1) | 24,100 | $732.2K |
| June 25, 2026 | Bergmann AnthonyCHIEF FINANCIAL OFFICER | Exercised options | 24,100 | $76.6K |
| June 25, 2026 | Bergmann AnthonyCHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 24,100 | $732.2K |
| June 24, 2026 | Krasney KarenEVP, GENERAL COUNSEL | Exercised options | 400 | $1.3K |
| June 24, 2026 | Krasney KarenEVP, GENERAL COUNSEL | Soldpre-planned (10b5-1) | 400 | $12K |
| June 24, 2026 | Bergmann AnthonyCHIEF FINANCIAL OFFICER | Exercised options | 400 | $1.3K |
| June 24, 2026 | Bergmann AnthonyCHIEF FINANCIAL OFFICER | Soldpre-planned (10b5-1) | 400 | $12K |
Who owns CAPR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tang Capital Management, LLC13G, passive with 5 related filers | 7.1% | August 14, 2026 |
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 6.6% | February 26, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 5.2% | August 3, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 170 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 4,145,061 | +723,246 |
| Tang Capital Management LLC | 4,099,900 | +700,000 |
| Montanova Capital, LLC | 4,092,784 | +274,184 |
| State Street Corp | 3,397,150 | +1,215,249 |
| Vanguard Capital Management LLC | 2,297,674 | +269,942 |
| Goldman Sachs Group Inc | 1,578,131 | +666,155 |
| RA Capital Management, L.P. | 1,507,844 | 0 |
| Boxer Capital Management, LLC | 1,395,156 | +805,156 |
| Geode Capital Management, LLC | 1,372,286 | +253,960 |
| Fmr LLC | 1,137,730 | +365,081 |
| Citadel Advisors LLC | 814,444 | +275,212 |
| Mercer Global Advisors Inc | 802,732 | +399,733 |
| Soleus Capital Management, L.P. | 761,737 | new |
| Morgan Stanley | 684,515 | +260,696 |
| Vanguard Portfolio Management LLC | 636,087 | +256,873 |
| UBS Group AG | 619,661 | +247,677 |
| DG Capital Management, LLC | 611,595 | +219,499 |
| Ikarian Capital, LLC | 604,215 | +76,200 |
| Northern Trust Corp | 503,532 | +85,989 |
| Balyasny Asset Management L.P. | 486,836 | +189,713 |
Insiders
4 insiders reported holding 189,852 shares in total, about $1.7M at the last price.
| Holder | Shares |
|---|---|
| Litvack FrankDirector | 133,776 |
| Krasney KarenEVP, GENERAL COUNSEL | 30,547 |
| Dunbar George W JrDirector | 14,306 |
| Bergmann AnthonyCHIEF FINANCIAL OFFICER | 11,223 |
Questions about CAPR
What does Capricor Therapeutics, Inc. do?
Capricor Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as CAPR. Its shares trade on NASDAQ under the ticker CAPR.
What is Capricor Therapeutics, Inc.'s net worth?
Capricor Therapeutics, Inc. has a market value (market cap) of $515.7M at the latest share price, and shareholders' equity of $246.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Capricor Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $129.4M.
When did Capricor Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from October 14, 2026.
When is Capricor Therapeutics, Inc.'s next earnings report?
Capricor Therapeutics, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare CAPR with
Follow CAPR
Get an email when Capricor Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Capricor Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.